Tradestie Institutional Equity Comparison Engine

ABCL vs QQEW โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABCL Overall Edge

ABCL Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ABCL trades at 27.6x Forward P/E with -1550.0% operating margin (-76.3% YoY revenue) versus QQEW at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ABCL sits in CONSOLIDATION (25th %ile IV; Dealer Gamma Walls on Pro) against QQEW sits in UNCLASSIFIED (86th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ABCL
ABCL 27.6x vs QQEW N/M Fwd P/E
Growth & Margin Winner ABCL
Op Margin -1550.0% vs N/A ยท YoY -76.3% vs N/A
Momentum & Technical Winner ABCL
1Y +209.0% vs +4.1% ยท 52W Pos 69% vs 52%
Options & Structure Winner ABCL
CONSOLIDATION (25th %ile IV) vs UNCLASSIFIED (86th %ile IV)
ABCL NASDAQ
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$11.19
-2.65% 1D
Market Cap $3.8B
1M Return -5.21%
1Y Return +208.98%
Forward P/E 27.6x
Unified AI Score
60.7 / 100 BUY
Tech 52.0 Fund 59.0 Flow 67.0 Mom 54.0
QQEW NASDAQ
First Trust NASDAQ-100 Equal Weighted Index Fund
Institutional Equity
$145.79
-2.13% 1D
Market Cap N/A
1M Return -5.73%
1Y Return +4.1%
Forward P/E N/M
Unified AI Score
58.9 / 100 HOLD
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABCL +208.98% QQEW +4.1% Spread: +204.88 pp (ABCL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABCL TTM Op. Margin: -1550.0% QQEW TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABCL vs QQEW. Trailing 12-month operating profitability (ABCL -1550.0% vs QQEW N/A) and valuation multiples (ABCL 27.6x vs QQEW N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABCL (9) vs QQEW (1)
Institutional Metric ABCL QQEW Criterion Row Winner
Market Capitalization Scale $3.8B N/A Larger Scale ABCL
Trailing P/E Ratio Valuation 27.6x N/M Lower Multiple ABCL
Forward P/E Ratio Valuation 27.6x N/M Lower Multiple ABCL
Revenue Growth (YoY) Growth -76.3% N/A Higher Growth ABCL
Operating Margin (TTM) Profitability -1550.0% N/A Higher Margin ABCL
Net Profit Margin Profitability -248.8% N/A Higher Margin ABCL
Return on Equity (ROE) Capital Efficiency -17.3% N/A Higher ROE ABCL
52-Week Range Position Momentum 69% ($3โ€“$15) 52% ($122โ€“$167) Stronger Trend ABCL
Beta / 30D Volatility Risk Regime 2.31ฮฒ ยท 87% Vol 1.33ฮฒ ยท 34% Vol Lower Realized Risk QQEW
Unified Institutional Score Composite Signal 60.7 / 100 (BUY) 58.9 / 100 (HOLD) Higher Composite ABCL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABCL vs QQEW Buy Guide
ABCL CONSOLIDATION
34d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 25th %ile
IV Regime Compressed (<25th %ile)
Live ABCL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
QQEW UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 86th %ile
IV Regime Extreme (>80th %ile)
Live QQEW Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABCL nor QQEW registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.